Evidence map›Paper›PMID 39379960›Full record

ArticleBMC medicine2024

Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER

Philipp Zimmer, Tobias Esser, Diana Lueftner, Florian Schuetz, Freerk T Baumann, Achim Rody, Andreas Schneeweiss, Andreas D Hartkopf, Thomas Decker, Christoph Uleer and 13 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Exercise therapy in cancer prevention and treatment.Nature reviews. Clinical oncology · 2026
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Philipp ZimmerInstitute for Sport and Sport Science, Division of Performance and Health (Sports Medicine), TU Dortmund University, Dortmund, Germany. philipp.zimmer@tu-dortmund.de.
Tobias EsserInstitute for Sport and Sport Science, Division of Performance and Health (Sports Medicine), TU Dortmund University, Dortmund, Germany.
Diana LueftnerImmanuel Hospital Märkische Schweiz, AND Medical University of Brandenburg Theodor Fontane, BuckowRüdersdorf Bei Berlin, Germany.
Florian SchuetzDepartment of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Freerk T BaumannDepartment I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Achim RodyDepartment of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Andreas SchneeweissNational Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Andreas D HartkopfDpt. of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Thomas DeckerMedical Center for Hematology and Oncology Ravensburg, Ravensburg, Germany.
Christoph UleerGynecologic Group Practice, Hildesheim, Germany.
Oliver J StoetzerMedical Center for Hematology and Oncology Munich, Munich, Germany.
Frank FoersterPoliklinik GmbH Chemnitz, Chemnitz, Germany.
Marcus SchmidtDpt. of Obstetrics and Gynecology, Dpt. of Conservative and Molecular Gynecological Oncology, University Medical Center Mainz, Mainz, Germany.
Christoph MundhenkeDepartment of Obstetrics and Gynecology, Bayreuth Hospital, Bayreuth, Germany.
Karen SteindorfGerman Cancer Research Center, Division of Physical Activity, Prevention and Cancer, Heidelberg, Germany.
Hans TeschCenter for Hematology and Oncology Bethanien, Frankfurt, Germany.
Christian JackischDpt. of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany.
Thomas FischerWinicker Norimed GmbH Medical Research, Nuernberg, Germany.
Sven HansonNovartis Pharma GmbH, Nuernberg, Germany.
Julia KreuzederNovartis Pharma GmbH, Nuernberg, Germany.
Gernot GuderianNovartis Pharma GmbH, Nuernberg, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.
Wilhelm BlochDpt. for Molecular and Cellular Sports Medicine, German Sport University Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and cohort studies have focused on associations between overall leisure time physical activity and survival of women with breast cancer in general.

methodsIn this multicenter prospective cohort study, conducted in Germany between 30th August 2012 to 29th December 2017, we investigated general physical activity in a homogenous sample of n = 1440 postmenopausal women with advanced (inoperable locally advanced or metastatic), hormone receptor-positive breast cancer receiving the same therapy (everolimus and exemestane). Self-reported physical activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) before and every 3 months during treatment. Participants were then classified into "active" and "insufficiently active" to screen their activity behavior the week prior to medical treatment. In addition, changes in physical activity patterns were assessed. Adjusted Cox regression analyses were performed for the activity categories to determine hazard ratios (HR). Besides progression-free survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 3 months until study termination.

resultsCompared to "insufficiently active" patients, "active" individuals indicated a significantly longer PFS (HR: 0.84 [0.74; 0.984], p = .0295). No significant differences were observed for changes of physical activity behavior. Patients who reported to be "active" at baseline revealed significantly fewer AEs compared to "insufficiently" active patients. In detail, both severe and non-severe AEs occurred less frequently in the "active" patients group. In line with that, QoL and fatigue were better in physical "active" patients compared to their insufficient active counterparts at the last post-baseline assessment. Participants who remained or become active indicated less AEs, a higher QoL, and reduced fatigue levels.

conclusionsPhysical activity behavior prior to medical treatment might have prognostic value in patients with advanced breast cancer in terms of extending the PFS. Moreover, physical activity before and during treatment may reduce treatment-related side effects and improve patients' QoL and fatigue.

trial registrationEUPAS9462. Registered 30th October 2012 "retrospectively registered."

Indexed as

Breast NeoplasmsExerciseAgedAndrostadienesEverolimusFatigueFemaleGermanyHumansMiddle AgedPostmenopauseProgression-Free SurvivalProspective StudiesQuality of LifeReceptors, EstrogenAndrostadienesEverolimusexemestaneReceptors, EstrogenAdverse eventsBreast cancerExerciseFatiguePhysical activityQuality of lifeSurvival

Identifiers

PMID39379960
PMCPMC11462731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.